Unstable angina non ST elevation myocardial infarction complications of bleeding and transfusion prognosis

Jump to navigation Jump to search


Intern
Survival
Guide

Acute Coronary Syndrome Main Page

Unstable angina / NSTEMI Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Unstable Angina
Non-ST Elevation Myocardial Infarction

Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders

Epidemiology and Demographics

Risk Stratification

Natural History, Complications and Prognosis

Special Groups

Women
Heart Failure and Cardiogenic Shock
Perioperative NSTE-ACS Related to Noncardiac Surgery
Stress (Takotsubo) Cardiomyopathy
Diabetes Mellitus
Post CABG Patients
Older Adults
Chronic Kidney Disease
Angiographically Normal Coronary Arteries
Variant (Prinzmetal's) Angina
Substance Abuse
Cardiovascular "Syndrome X"

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Blood Studies
Biomarkers

Electrocardiogram

Chest X Ray

Echocardiography

Coronary Angiography

Treatment

Primary Prevention

Immediate Management

Anti-Ischemic and Analgesic Therapy

Cholesterol Management

Antitplatelet Therapy

Antiplatelet therapy recommendations
Aspirin
Thienopyridines
Glycoprotein IIb/IIIa Inhibitor

Anticoagulant Therapy

Additional Management Considerations for Antiplatelet and Anticoagulant Therapy

Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS

Mechanical Reperfusion

Initial Conservative Versus Initial Invasive Strategies
PCI
CABG

Complications of Bleeding and Transfusion

Discharge Care

Medical Regimen
Post-Discharge Follow-Up
Cardiac Rehabilitation

Long-Term Medical Therapy and Secondary Prevention

ICD implantation within 40 days of myocardial infarction

ICD within 90 days of revascularization

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Unstable angina non ST elevation myocardial infarction complications of bleeding and transfusion prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Unstable angina non ST elevation myocardial infarction complications of bleeding and transfusion prognosis

CDC onUnstable angina non ST elevation myocardial infarction complications of bleeding and transfusion prognosis

Unstable angina non ST elevation myocardial infarction complications of bleeding and transfusion prognosis in the news

Blogs on Unstable angina non ST elevation myocardial infarction complications of bleeding and transfusion prognosis

to Hospitals Treating Unstable angina non ST elevation myocardial infarction complications of bleeding and transfusion prognosis

Risk calculators and risk factors for Unstable angina non ST elevation myocardial infarction complications of bleeding and transfusion prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Template:MWT; Cafer Zorkun, M.D., Ph.D. [2]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.

Overview

Regardless of which bleeding definition is utilized, multiple studies have demonstrated a clear association between bleeding in the NSTEMI population and adverse outcomes including death, stroke, MI and unplanned revascularization.

Clinical Trial Data

  • Moscucci and colleagues examined the GRACE registry of 24,045 patients with ACS (including unstable angina, NSTEMI, and STEMI) and found an association between GRACE major bleeding and increased in-hospital mortality.[1]
  • An analysis by Rao et al.,[2] examined 26,452 ACS-patients enrolled in the PURSUIT, PARAGON B, and GUSTO IIb trials and demonstrated an increased in risk between bleeding severity and 30-day and 6-month death.
  • Eikelboom et al.,[3] and Manoukian et. al.,[4] have described a similar, significant association between major bleeding in NSTEMI and unstable angina patients and adverse outcomes.

Prognosis Between TIMI and GRACE Scales

  • The prognostic significance of different bleeding definitions (GUSTO vs TIMI) was assessed by Rao and colleagues.
  • Both GUSTO and TIMI bleeding were associated with an increased risk for 30-day death or MI when examined separately. When both definitions were included in the same model, increasing GUSTO bleeding severity was associated with a stepwise increase in the adjusted hazard of death or MI, whereas TIMI bleeding did not correlate with prognosis.

Therefore, bleeding defined by clinical events is likely more important in terms of prognosis rather than bleeding defined solely on the basis of reductions in hemoglobin concentration.

Mechanisms of Bleeding and Increased Mortality

Despite the strong association between bleeding and adverse ischemic events, the direct causality of bleeding complications and adverse ischemic events remains uncertain.

Anemia and Anemia induced Hemodynamic Compromise

  • During NSTEMI/unstable angina, oxygen delivery to the hypoxic myocardium is normally augmented by a compensatory coronary vasodilatory response.
  • Stenotic coronary vessels are devoid of the vasodilatory response and therefore compensatory increases in heart rate and myocardial contractility are employed to maintain systemic oxygen demands.
  • The pathophysiology underlying poor outcomes in anemic-NSTEMI patients may be explained by the combination of reduced oxygen delivery to the already hypoxic myocardium and the high myocardial oxygen demand secondary to the compensatory increases in heart rate and stroke volume.

Bleeding therefore, may worsen myocardial ischemia in the NSTEMI patient by inducing a mild anemia and state of tissue hypoperfusion. The subsequent, compensatory tachycardiac and upregulated myocardial contractility state result in a deleterious, myocardial oxygen supply and demand disparity.[5]

Potentiation of the Inflammatory Response

  • Bleeding events precipitate recurrent ischemic events by potentiating the inflammatory response through activation of the platelet and coagulation cascades.

Reception of Packed Red Blood Cells

  • Mechanistic studies have shown that transfusion of red cells paradoxically does not improve oxygen delivery.[6]
  • Stored blood is characterized by an increased affinity for oxygen because of decreased 2,3 DPG levels.
  • Stored RBCs have alterations in their morphology and adhesion properties which many speculate increases the risk of vessel occlusion.
  • Stored RBCs, devoid of NO produces vasoconstriction, platelet aggregation, and ineffective oxygen delivery.
  • Nitric oxide is essential for oxygen uptake into tissues and is the most potent vasodilator.

The synergistic effects of high oxygen affinity and ineffective oxygen delivery of RBC transfusion may account, in part, for poor outcomes among transfused NSTEMI patients.

Cessation of Antiplatelet and/or Antithrombin Therapies

  • Analyzing the GRACE database of NSTEMI patients who suffered major bleeding (n=506) within 2 days of admission, Spencer and colleagues discovered that NSTEMI patients with a bleeding event were less likely to have received ASA, thienopyridines, unfractionated heparin or low-molecular-weight heparin during their hospitalization.
  • Mortality rates among ACS patients who experienced a major bleeding event were higher if aspirin (OR, 7.55 (95% CI, 4.43 to 12.88)); thienopyridines, (OR, 8.91 (95% CI, 4.39 to 18.12)); and unfractionated heparin, (OR, 1.91 (95% CI, 1.09 to 3.36)) were discontinued, compared to NSTEMI patients who experienced a major bleeding event but continued therapy with these agents.[7]

References

  1. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815–23.
  2. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Harrington RA. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:809–16.
  3. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–82.
  4. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, Ohman EM, Stone GW. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49:1362-8.
  5. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111:2042–2049.
  6. Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, Gernert K, Piantadosi CA. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science. 1997;276:2034–2037.
  7. Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, Goodman SG, Budaj A, Fitzgerald G, Fox KA; for the GRACE Investigators. Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction? Circulation. 2007;116:2793-801.


Template:WikiDoc Sources